Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Capecitabine
/ therapeutic use
Chemotherapy, Adjuvant
Colorectal Neoplasms
/ drug therapy
Fluorouracil
/ adverse effects
Hepatectomy
Humans
Liver Neoplasms
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Oxaliplatin
/ therapeutic use
Adjuvant chemotherapy
CAPOX
CapeOx
Colorectal liver metastases
XELOX
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
28
01
2021
accepted:
27
04
2021
pubmed:
13
5
2021
medline:
13
7
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
Three-month adjuvant capecitabine plus oxaliplatin in combination (CAPOX) appeared to reduce recurrence, with mild toxicity in postcurative resection of colorectal cancer liver metastases (CLM). Recurrence in patients who underwent the 3-month adjuvant CAPOX after resection of CLM was most commonly at extrahepatic sites. The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3-month adjuvant treatment with capecitabine plus oxaliplatin in combination (CAPOX) for postcurative resection of CLM. Patients received one cycle of capecitabine followed by four cycles of CAPOX as adjuvant chemotherapy after curative resection of CLM. Oral capecitabine was given as 1,000 mg/m Twenty-eight patients were enrolled. Median age was 69.5 years, 54% of patients had synchronous metastases, and 29% were bilobar. Mean number of lesions resected was two, and mean size of the largest lesion was 31 mm. Among patients, 20 (71.4%; 95% confidence interval, 53.6%-89.3%) completed the protocol treatment and met its primary endpoint. The most common grade 3 or higher toxicity was neutropenia (29%). Five-year recurrence-free survival and overall survival were 65.2% and 87.2%, respectively. Three-month adjuvant treatment with CAPOX is tolerable and might be a promising strategy for postcurative resection of CLM.
Sections du résumé
LESSONS LEARNED
Three-month adjuvant capecitabine plus oxaliplatin in combination (CAPOX) appeared to reduce recurrence, with mild toxicity in postcurative resection of colorectal cancer liver metastases (CLM). Recurrence in patients who underwent the 3-month adjuvant CAPOX after resection of CLM was most commonly at extrahepatic sites.
BACKGROUND
The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3-month adjuvant treatment with capecitabine plus oxaliplatin in combination (CAPOX) for postcurative resection of CLM.
METHODS
Patients received one cycle of capecitabine followed by four cycles of CAPOX as adjuvant chemotherapy after curative resection of CLM. Oral capecitabine was given as 1,000 mg/m
RESULTS
Twenty-eight patients were enrolled. Median age was 69.5 years, 54% of patients had synchronous metastases, and 29% were bilobar. Mean number of lesions resected was two, and mean size of the largest lesion was 31 mm. Among patients, 20 (71.4%; 95% confidence interval, 53.6%-89.3%) completed the protocol treatment and met its primary endpoint. The most common grade 3 or higher toxicity was neutropenia (29%). Five-year recurrence-free survival and overall survival were 65.2% and 87.2%, respectively.
CONCLUSION
Three-month adjuvant treatment with CAPOX is tolerable and might be a promising strategy for postcurative resection of CLM.
Identifiants
pubmed: 33977607
doi: 10.1002/onco.13816
pmc: PMC8265340
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Capecitabine
6804DJ8Z9U
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1125-e1132Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Lancet. 2008 Mar 22;371(9617):1007-16
pubmed: 18358928
Chirurg. 2001 May;72(5):547-60
pubmed: 11383067
Gut. 2006 Aug;55 Suppl 3:iii1-8
pubmed: 16835351
Clin Epidemiol. 2012;4:283-301
pubmed: 23152705
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Jpn J Clin Oncol. 2009 Jun;39(6):406-9
pubmed: 19389795
J Clin Oncol. 2006 Nov 1;24(31):4976-82
pubmed: 17075115
Cancer. 1996 Apr 1;77(7):1254-62
pubmed: 8608500
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
JAMA Oncol. 2019 Aug 1;5(8):1124-1131
pubmed: 31070691
PLoS One. 2016 Sep 02;11(9):e0162400
pubmed: 27588959
J Clin Oncol. 2008 Oct 20;26(30):4906-11
pubmed: 18794541
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
J Clin Oncol. 1997 Mar;15(3):938-46
pubmed: 9060531